%0 Journal Article
%T Study of the Effects of Glucocorticoid on Growth and Adult Final Height in Children with Primary Nephrotic Syndrome
%A Fazhan Zhong
%A Miao Zhang
%A Yan Gao
%J Open Journal of Nephrology
%P 1-9
%@ 2164-2869
%D 2024
%I Scientific Research Publishing
%R 10.4236/ojneph.2024.141001
%X <strong>Objective:</strong> To analyze the epidemiological characteristics of growth, as well as factors associated with growth retardation in children with primary nephrotic syndrome (PNS), and to investigate the effect of glucocorticoid (GC) use duration on growth retardation in these children. <strong>Methods:</strong> Clinical and laboratory data of 353 PNS children treated at our hospital from July 2014 to June 2015 were collected through the medical record management system. Height, weight, and GC usage were recorded. Follow-up assessments were conducted in August 2022 for the original group, recording height, weight, and GC usage. Height and weight were evaluated using standard deviation scores (SDS). Categorical data were analyzed using chi-square test while continuous measurement data were analyzed using t-test or rank-sum test. Linear regression was used to assess the association between two single independent variables, and logistic regression analysis was used to screen for risk factors related to growth retardation in children with PNS. <strong>Results:</strong> Among the 353 PNS children enrolled in this study, male-to-female ratio of 2.64:1 (256 males vs 97 females). A total of 119 children exhibited growth retardation, incidence rate of 33.71%. The duration of GC usage among those with growth retardation was significantly longer compared to those without it (762.81 ¡À 934.50 days vs 263.77 ¡À 420.49 days; p &lt; 0.05). There was a negative correlation between GC usage duration and height SDS (r = -0.406; p &lt; 0.05). Telephone follow-up was conducted on 61 patients, with 14 (22.95%) exhibiting growth retardation. Among the 34 patients who reached final adult height, 11 (32.35%) was in the growth retardation group, accounting for 64.28% of the total growth retardation cases (9 out of 14). <strong>Conclusion:</strong> PNS children treated with GC have a high incidence of growth retardation, and a high proportion of short stature in adulthood, especially in children with growth retardation in childhood, most of them have short stature after grown up. Time of GC usage is a risk factor for growth retardation in children with PNS.
%K Primary Nephrotic Syndrome
%K Glucocorticoid
%K Children
%K Growth Retardation
%K Adult Height
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=130416